All In Biotech

NDA 022325 · Baxter Hlthcare

Nexterone

Amiodarone Hydrochloride · Injection

Last checked: Nov 20, 2026Latest source record: Feb 21, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2008

Dec 24, 2008

Approved uses

1

Original approval plus efficacy supplements

Registered trials

185

52 Phase 3, 17 recruiting

FAERS reports

9,437

8,191 serious, 1,606 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Apr 16, 2024.

NEXTERONE is indicated for initiation of treatment and prophylaxis of frequently recurring ventricular fibrillation (VF) and hemodynamically unstable ventricular tachycardia (VT) in patients refractory to other therapy. NEXTERONE is an antiarrhythmic agent indicated for treatment and prophylaxis of ventricular fibrillation (VF) and hemodynamically unstable ventricular tachycardia (VT) in patients refractory to other therapy. (1)

Mechanism: Amiodarone is considered a class III antiarrhythmic drug, but it possesses electrophysiologic characteristics of all four Vaughan Williams classes. Like class I drugs, amiodarone blocks sodium channels at rapid pacing frequencies, and like class II drugs, amiodarone exerts a noncompetitive antisympathetic action. One of its main effects, with prolonged administration, is to lengthen the cardiac action potential, a class III effect. The negative chronotropic effect of amiodarone in nodal tissues is similar to the effect of class IV drugs. In addition to blocking sodium channels, amiodarone...

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

3 products under this application
  • NEXTERONE · AMIODARONE HYDROCHLORIDE 360MG/200ML (1.8MG/ML) · INJECTABLE, INJECTION · Prescription
  • NEXTERONE · AMIODARONE HYDROCHLORIDE 50MG/ML **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · INJECTABLE, INJECTION · Discontinued
  • NEXTERONE · AMIODARONE HYDROCHLORIDE 150MG/100ML (1.5MG/ML) · INJECTABLE, INJECTION · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Amiodarone" as an intervention, any sponsor and status, largest first.

All 185 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • dyspnoea1,008
  • off label use869
  • asthenia837
  • fatigue779
  • drug ineffective712
  • product use in unapproved indication648
  • nausea548
  • cough532
  • atrial fibrillation476
  • dizziness476
  • drug interaction454
  • pneumonia452

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
200459
2005106
200683
200768
200841
2009108
2010119
2011140
2012338
2013144
2014149
2015187
2016218
2017504
2018500
2019619
2020605
2021843
2022940
2023941
20241,058
20251,049
2026616

Recalls

2 FDA enforcement reports for this application.

  • Aug 6, 2026 · Class II · Ongoing

    CGMP Deviations

  • Nov 10, 2017 · Class I · Terminated

    Presence of Particulate Matter:Particulate identified as polyethylene, the primary constituent of the film and ports used to manufacture the bag in which product is packaged

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 1,018 on PubMed

Sponsor: Baxter Hlthcare

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.